These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21155698)

  • 1. Economic impact of hypoglycemia on healthcare in Spain.
    Brito-Sanfiel M; Diago-Cabezudo J; Calderon A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):649-60. PubMed ID: 21155698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology and the issue of cost/benefit in diabetes.
    Giannini C; Mohn A; Chiarelli F
    Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic effect of hypoglycemia in a health plan.
    Heaton A; Martin S; Brelje T
    Manag Care Interface; 2003 Jul; 16(7):23-7. PubMed ID: 12908214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of non-severe hypoglycemic events on work productivity and diabetes management.
    Brod M; Christensen T; Thomsen TL; Bushnell DM
    Value Health; 2011; 14(5):665-71. PubMed ID: 21839404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.
    Reviriego J; Gomis R; Marañés JP; Ricart W; Hudson P; Sacristán JA
    Int J Clin Pract; 2008 Jul; 62(7):1026-32. PubMed ID: 18489577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of hypoglycemia in patients with Type 2 diabetes.
    Liu S; Zhao Y; Hempe JM; Fonseca V; Shi L
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):47-51. PubMed ID: 22280196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of managing severe hypoglycaemia in three European countries.
    Hammer M; Lammert M; Mejías SM; Kern W; Frier BM
    J Med Econ; 2009; 12(4):281-90. PubMed ID: 20001570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
    Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
    J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States.
    Foos V; Varol N; Curtis BH; Boye KS; Grant D; Palmer JL; McEwan P
    J Med Econ; 2015 Jun; 18(6):420-32. PubMed ID: 25629654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance.
    Unger J; Parkin C
    Postgrad Med; 2011 Jul; 123(4):81-91. PubMed ID: 21680992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
    Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
    J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characterisation of severe hypoglycaemia--a prospective population-based study.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):364-9. PubMed ID: 14520604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Costs of known diabetes mellitus in Spain].
    Hart WM; Espinosa C; Rovira J
    Med Clin (Barc); 1997 Sep; 109(8):289-93. PubMed ID: 9379750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycaemia: costs, insulins and prevention.
    Holt RI
    Diabet Med; 2016 Apr; 33(4):419-20. PubMed ID: 26995756
    [No Abstract]   [Full Text] [Related]  

  • 20. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.